NOLA M. KLEMFUSS

HEALTHCARE LEADER *****BUSINESS ADMINISTRATOR

Tenacious, results-oriented, and priority-driven professional with a Masters in Health Administration (MHA), with 15+ years of experience in project leadership and administration in healthcare. Proven ability to manage multiple projects and execute job duties with efficiency and integrity. Capable problem solver with solid business acumen, collaborator able to employ strategic vision to foster transformational change.

Leadership | Financial Management & Analysis | Budget Forecasting | Relationship Building | Process Improvement | Business Management | Regulatory Compliance | Policies & Procedures | Quality Assurance

PROFESSIONAL EXPERIENCE

ADMINISTRATIVE DIRECTOR, BROTMAN BATY INSTITUTE FOR PRECISION MEDICINE, University of Washington, Seattle, WA June 2019 – Present

• Responsible for all administrative and operational activities of the institute, and built the program from the ground up. Oversight of finance, strategy, legal contracting, procurement, facilities, construction and support of research.

• Drive strategic growth of the institute by overseeing scientific projects, negotiating new collaborations and scaling administrative and technical capabilities by developing new administrative and technical processes and systems as institute grows in size and complexity.

• Hired and develop a cross-functional team responsible for all project management, procurement, finance and communications for the institute, support professional development and mentoring of staff and students

• Maintain effective and collaborative working relationships with stakeholders and partners across all 3 member institutions, the University of Washington, Fred Hutch Cancer Research Center and Seattle Children's.

• Utilize highly developed communication skills and flexibility to resolve conflict, encourage teamwork to achieve organizational initiatives.

• Ensure financial growth, stability, donor relationships and compliance for \$100M of institute funding.

• Navigate new challenges with poise and enthusiasm. For example, in 2020, supported the Seattle Flu Study, a project within the institute, scale up operations from a small research study into a large scale clinical COVID-19 testing service known as the Seattle Coronavirus Assessment Network (SCAN), managing challenges related to regulatory, supply chain, operations and communications in a high stress and uncertain environment.

PROGRAM MANAGER, BROTMAN BATY INSTITUTE FOR PRECISION MEDICINE, University of Washington, Seattle, WA December 2017-June, 2019

- Built administrative infrastructure for the institute in partnership with institute leadership
- Launched granting program, scientific working groups and operational processes

PROGRAM MANAGER, INSTITUTE FOR PROSTATE CANCER RESEARCH, University of Washington & Fred Hutch Cancer Research Center, Seattle, WA July 2013-June, 2019

• Lead precision oncology pilot to initiate prostate cancer tumor sequencing and interpretation into clinical practice, leading to multiple publications

• Developed a germline genetic testing study to provide men with advanced metastatic prostate cancer access to genetic testing, cascade testing for affected family members, and targeted therapies

• Designed statewide cancer registry website to track the clinical and quality of life outcomes of all prostate cancer patients across the state; collaborated with Department of Health, local and state IRBs, as well as advocacy networks; managed web development team to build a HIPAA-compliant, secure survey tool

• Managed program finances across UW and Fred Hutch budgets, managed pilot program and disbursement of awards

• Organized patient symposia, prepared communications with our donor community

PROGRAM COORDINATOR, SEATTLE TRANSLATIONAL TUMOR RESEACH, Fred Hutch Cancer Research Center, Seattle, WA July 2013-June, 2019

• Directed 2 solid tumor and 4 hematologic malignancy programs in efforts to speed translational cancer research by fostering new collaborations, guiding strategy, and supporting program infrastructure for precision medicine

ADMINISTRATIVE FELLOW, UNIVERSITY OF WASHINGTON MEDICAL CENTER, Seattle, WA June 2012 – July 2013

•Provided project management for executive team, reporting directly to Executive Director

•Developed and used financial data analyses to support strategic decision making

EDUCATION & CERTIFICATIONS

Master of Health Administration – University of Washington, Seattle, WA Bachelor of Arts, Social Sciences – University of California, Berkeley, Berkeley, CA

AWARDS

Winner of the 2020 "Together We Will" award to celebrate UW staff who demonstrated excellence and made a significant impact during the tremendous challenges of 2020.

SELECTED PUBLICATIONS

Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference, Jensen K, Konnick, E, Schweizer, M, Sokolova A, Grivas P, Cheng, H, **Klemfuss N**, Beightol M, Yu E, Nelson, P, Montgomery, N, Pritchard, C JAMA Oncol 2021 Jan 1;7(1):107-110.doi: 10.1001/jamaoncol.2020.5161.

Microsatellite instability in prostate cancer by PCR or next-generation sequencing. Hempelmann JA, Lockwood CM, Konnick EQ, Schweizer MT, Antonarakis ES, Lotan TL, Montgomery B, Nelson PS, **Klemfuss N**, Salipante SJ, Pritchard CC. J Immunother Cancer. 2018 Apr 17;6(1):29. doi:10.1186/s40425-018-0341-y.PMID: 29665853

Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations.Schweizer MT, Antonarakis ES, Bismar TA, Guedes LB, Cheng HH, Tretiakova MS, Vakar-Lopez F, **Klemfuss N**, Konnick EQ, Mostaghel EA, Hsieh AC, Nelson PS, Yu EY, Montgomery RB, True LD, Epstein JI, Lotan TL, Pritchard CC.JCO Precis Oncol. 2019;3:10.1200/PO.18.00327. doi:10.1200/PO.18.00327. Epub 2019 Apr 18.PMID: 31123724

Clinical determinants for successful circulating tumor DNA analysis in prostate cancer.Schweizer MT, Gulati R, Beightol M, Konnick EQ, Cheng HH, **Klemfuss N**, De Sarkar N, Yu EY, Montgomery RB, Nelson PS, Pritchard CC.Prostate. 2019 May;79(7):701-708. doi: 10.1002/pros.23778. Epub 2019 Mar 13.PMID: 30865311

Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate. Schweizer MT, Cheng HH, Tretiakova MS, Vakar-Lopez F, **Klemfuss N**, Konnick EQ, Mostaghel EA, Nelson PS, Yu EY, Montgomery B, True LD, Pritchard CC. Oncotarget. 2016 Dec 13;7(50):82504-82510. doi: 10.18632/oncotarget.12697.PMID: 27756888